As China’s biotech firms shift gears, can AI floor the accelerator?
SCMP Tech / 4/18/2026
💬 OpinionIdeas & Deep AnalysisIndustry & Market MovesModels & Research
Key Points
- Chinese biotech and pharmaceutical firms are increasingly landing large global licensing deals, with recent transactions involving CSPC Pharmaceutical, RemeGen, and Haisco Pharmaceutical Group at multi-billion-dollar scales.
- The article frames this surge as a potential inflection point for the industry, shifting attention from dealmaking volume toward how new capabilities—particularly AI—could improve drug discovery and development.
- It poses the central question of whether artificial intelligence can help Chinese firms “floor the accelerator” by accelerating R&D cycles or improving outcomes beyond traditional approaches.
- The discussion suggests that as deal activity becomes more common, differentiation will likely depend on operational and scientific efficiency gains, where AI may be a key lever.
- Overall, the piece connects China’s biotech market momentum with the strategic role of AI as a next-stage accelerator for growth and competitiveness.
A quarter featuring multiple eye-popping deals is no longer unusual for China’s pharmaceutical industry – in fact, it may soon be considered a slow season.
In recent months, companies including CSPC Pharmaceutical and RemeGen have struck out-licensing agreements worth up to US$18.5 billion and US$5.6 billion respectively, while Haisco Pharmaceutical Group has added two of its own — most recently a deal worth up to US$745 million.
Under the terms of the deal, the Beijing-based Haisco granted US...
Continue reading this article on the original site.
Read original →
